| Document |
Document Title |
|
WO/2012/058993 |
A use of ambrisentan or pharmaceutically acceptable salts thereof for preparing medicines for preventing or alleviating cardiac function injury or secondary diseases thereof caused by hypoxia, said secondary diseases being selected from ...
|
|
WO/2012/060448 |
The purpose of the invention is to provide a pharmaceutical composition having excellent antifungal activity. The invention provides a pharmaceutical composition comprising 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyrid
in-...
|
|
WO/2012/060396 |
The purpose of the present invention is to provide a novel trans-2-decenoic acid derivative and a pharmaceutically acceptable salt thereof, and a medicament containing the compound described above as an active component and having a neur...
|
|
WO/2012/058935 |
The present invention discloses total polysaccharides of radix isatidis and their polysaccharide fractions, wherein the polysaccharide fractions comprise rhamnose, arabinose, xylose, mannose, glucose and galactose with specific molar rat...
|
|
WO/2012/061597 |
Compounds that bind to acid alpha glucosidase are described. Methods of using these compounds for the treatment of diabetes and Pompe disease are also described.
|
|
WO/2012/060308 |
Provided is a medicine for preventing and treating renal dysfunction. That is, there is provided a medicine for preventing and treating renal dysfunction comprising, as active ingredients, a 1,2,4-triazole compound, a pharmaceutically ac...
|
|
WO/2012/060388 |
The purpose of the invention is to provide a novel organic amine salt or quaternary ammonium salt of the 3-{[((2E)-2-{1-[5-(4-t-butylphenyl)-4-hydroxy-3-thienyl]ethy
lidene}hydrazino)carbonothioyl]amino} benzoic acid represented by the f...
|
|
WO/2012/060323 |
Provided is a gene involved in the regulation of the amount of melanin in keratinocytes and the control of skin and hair color, said gene being selected from the group comprising the ATG7 gene, RAB11A gene, CLIP-170 gene, Rubicon gene, a...
|
|
WO/2012/057123 |
Provided in the present invention is a material which is produced by processing a material extracted from a plant seed using an organic solvent, and which is highly effective in promoting collagen production, promoting hyaluronan product...
|
|
WO/2012/057248 |
Provided, for example, are a compound described below and the like, which have amyloid β production inhibitory activity, especially BACE1 inhibitory effect and serve as therapeutic agents for diseases induced by the production, secretio...
|
|
WO/2012/057635 |
The invention provides a method of treating traumatic brain injury (TBI) by administering a composition comprising proanthocyanidins. The proanthocyanidins are preferably administered as an extract of pine bark that contains proanthocyan...
|
|
WO/2012/055826 |
The invention relates to the use of cystamine, cysteamine, or a salt thereof, or of calcineurin inhibitors for treating a MeCP2-associated disorder such as Rett syndrome.
|
|
WO/2012/057262 |
A pyridine derivative represented by general formula [1] or a pharmaceutically acceptable salt thereof. In formula [1], R represents an aryl group or a heteroaryl group, wherein each of the aryl group and the heteroaryl group may be subs...
|
|
WO/2012/057247 |
Provided, for example, are a compound described below and the like, which have amyloid β production inhibitory activity, especially BACE1 inhibitory effect and serve as therapeutic agents for diseases induced by the production, secretio...
|
|
WO/2012/056976 |
Provided is a novel compound capable of inhibiting cardiac adenylate cyclase. The compound is a compound represented by formula (I) or a pharmaceutically acceptable salt, ester or solvate thereof. (In the formula, R1, R2 and R3 independe...
|
|
WO/2012/056120 |
The subject matter of the invention is novel medicaments for modulating intracellular cholesterol concentration through the modulation of the Hedgehog (Hh) signalling pathway. The invention has applications particularly in the treatment ...
|
|
WO/2012/057288 |
The present invention relates to an antibody which has a therapeutic effect on cancer, autoimmune diseases or inflammatory diseases. Namely, the present invention relates to an antibody which exhibits an apoptosis-mediated cytotoxic acti...
|
|
WO/2012/056141 |
The present invention relates to a method for producing articles impregnated with at least one plant extract from at least one plant, characterized in that it comprises the following steps: a) extraction and/or pressing of at least one p...
|
|
WO/2012/057291 |
The present invention relates to a process for producing a phenolic polymerizable compound represented by formula (1) or (2) (wherein X1-X9 independently represent a hydrogen atom, a hydroxy group, a saturated or unsaturated linear or br...
|
|
WO/2012/053186 |
The present invention relates to arylamide derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage ...
|
|
WO/2012/053606 |
Provided is a compound useful as an inhibitor of the kinase activity of an EML4-ALK fusion protein or the like. The present inventors have made intensive studies on compounds useful for the treatment of cancer. Consequently, it is found ...
|
|
WO/2012/050162 |
The present invention provides: a novel cellular life span extending agent, particularly an agent for extending the life span of an endothelial cell, which comprises an extract derived from a plant belonging to the genus Cinnamomum; and ...
|
|
WO/2012/050181 |
Provided are: siRNA which is effective for treating fibrosis; and a medicine comprising the siRNA. The siRNA targets a sequence comprising contiguous 17-23 nucleotides selected from the group consisting of nucleotides lying between 1285t...
|
|
WO/2012/050184 |
The purpose of the present invention is to provide a pharmaceutical composition which comprises a medicinal agent and a collagen and has good handleability and sustained release properties. The purpose is achieved by a sustained-release ...
|
|
WO/2012/050159 |
The present invention relates to a novel amide derivative. More specifically, the present invention provides a medicinal agent useful as a prophylactic or therapeutic agent for diseases, which relies on the production of cytokines from T...
|
|
WO/2012/050895 |
Nutrient compositions comprising botanical extracts and methods of their use for treating, inter alia, autism or apraxia and/or ameliorating one or more symptoms thereof are disclosed. The use of such compositions for enhancing cognitive...
|
|
WO/2012/051505 |
Dosage units consist of an autologous cell therapy product composed of fibroblasts grown for each individual to be treated for augmentation or regeneration of vocal cords. The suspension of autologous fibroblasts, grown from a biopsy of ...
|
|
WO/2012/050151 |
Provided is a compound or a pharmaceutically acceptable salt thereof represented by general formula (I) which has an excellent blood glucose-lowering effect and protective effect on β cells or the pancreas, and also provided is a pharma...
|
|
WO/2012/050154 |
The present invention provides a therapeutic agent or a preventative agent containing anti-VDAC antibody for diseases in which there is increased activation of osteoclasts, such as rheumatoid arthritis, and an inhibitor of human osteocla...
|
|
WO/2012/046771 |
The inventors have intensively studied on compounds that have Aβ42 production inhibitory activity and have found that a compound (I) of the present invention, wherein a carboxylic acid or a tetrazole group is bonded to a cycloalkane moi...
|
|
WO/2012/046653 |
Provided is an ester of 3-[(4-dipropylamino-butyl)-(4-{[(1H-imidazole-2-ylmethyl)-(1
-methyl-1H-imidazole-2-ylmethyl)-amino]-methyl}-benzyl)-amin
o]-propionic acid which is easily hydrolyzed in serum. The amine compound of the present in...
|
|
WO/2012/046869 |
[Problem] To provide a GPR40 activator, particularly an insulin secretion stimulator or a prophylactic and/or therapeutic agent for diabetes, obesity or the like, which contains a novel compound having a GPR40 agonistic activity, a salt ...
|
|
WO/2012/045118 |
The invention relates to methods, uses and compositions for treating non-infectious diseases with a therapeutically effective amount of a pharmaceutical composition comprising methylsulfonylmethane, glucosamine, L-glycine, and vitamin B1...
|
|
WO/2012/046792 |
A compound represented by general formula (II) or a salt thereof, which is a GPR119 agonist, is used as a therapeutic agent for diabetes. In formula (II), Ar0 represents a phenyl group or the like which may be substituted with a substitu...
|
|
WO/2012/045285 |
Disclosed is a pharmaceutical composition containing a muscarinic receptor blocker and a cholinesterase inhibitor. The present pharmaceutical composition is used against septic shock, especially against endotoxin shock, and against crush...
|
|
WO/2012/046681 |
An objective of the present invention is to provide a pharmaceutical product which inhibits the expression of at least one lipid metabolism related mRNA that is selected from the group consisting of Angptl4 mRNA, SCD-1 mRNA and SREBP1c m...
|
|
WO/2012/045282 |
Provided are applications of arctigenin in formulating medicines for preventing or treating diseases related to blood cell reduction, and preparations that contain arctigenin, particularly micro-emulsions that contain arctigenin. Experim...
|
|
WO/2012/043838 |
The purpose of the present invention is to provide a highly safe drug which can effectively inhibit hepatitis C virus infection per se so as to prevent inflammation, differing from symptomatic treatments whereby various types of inflamma...
|
|
WO/2012/043638 |
Provided is a compound which is useful as a prophylactic or therapeutic agent for diseases or the like caused by abnormal serum urate level. An (aza)indolizine derivative represented by formula (I), said (aza)indolizine derivative having...
|
|
WO/2012/042951 |
Provided is a medicinal tablet, particularly an orally disintegrating tablet, in which unpleasant taste of atorbastatin in the oral cavity is reduced (drug compliance), and which can be dispersed or eluted rapidly in the digestive tract....
|
|
WO/2012/043533 |
The purpose of the present invention is to provide a novel antihuman CCR7 antibody which is useful as a therapeutic agent for tissue fibrosis or cancer, a medicinal composition which comprises the antihuman CCR7 antibody, and so on. Prov...
|
|
WO/2012/042915 |
The present invention relates to sulfamoyl benzoic acid heterobicyclic derivatives of the formula (I) or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions contai...
|
|
WO/2012/043185 |
Developed are a composition for inhibiting IL-8 expression which can be used daily and which is stable and safe, and an external preparation for the skin, a pharmaceutical composition and a food composition containing same. The present i...
|
|
WO/2012/042618 |
A composition for regenerating the follicle, which contains CD36-expressing connective tissue sheath cells (DSc).
|
|
WO/2012/039414 |
The present invention provides a compound having antiviral effects, particularly having growth inhibitory activity on influenza viruses, a preferred example of the compound being a substituted 3‑hydroxy-4‑pyridone derivative prodrug ...
|
|
WO/2012/039460 |
The present invention provides a substituted amide compound such as a compound represented by formula AA, which is useful as an active ingredient of a pharmaceutical composition, especially as an active ingredient of a pharmaceutical com...
|
|
WO/2012/039447 |
The purpose of the present invention is to provide potassium salts of substituted pyrrolidine derivatives, which inhibit the production of an inflammatory mediator caused by intracellular signal transduction or cell activation induced by...
|
|
WO/2012/039197 |
In the present invention TRAIL resistance was overcome in a malignant tumor resistant to TRAIL. By using an agent for enhancing TRAIL sensitivity comprising, as an active ingredient, an ATP-sensitive potassium channel inhibitor such as g...
|
|
WO/2012/040465 |
The invention provides a quiescent stem cell having the capacity to differentiate into ectoderm, mesoderm and endoderm, and which does not express cell surface markers including MHC class I, MHC class II, CD44, CD45, CD13, CD34, CD49c, C...
|
|
WO/2012/036233 |
Provided is a novel compound which has MCH R1 receptor antagonistic activity and is represented by formula (I), a pharmaceutically acceptable salt thereof, or a solvate of the same. (In the formula, the portion AA represented by formula ...
|
